1 Min Read
March 9 (Reuters) - Effector Therapeutics:
* Lead product candidate, EFT508, receives orphan designation from FDA for treatment of diffuse large B-cell lymphoma Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.